| Identification | Back Directory | [Name]
N-(1-acetyl-4-piperidinyl)-4-fluoro-BenzaMide | [CAS]
283167-06-6 | [Synonyms]
FK962
N-(1-acetylpiperidin-4-yl)-4-fluorobenzamide
N-(1-acetyl-4-piperidinyl)-4-fluoro-BenzaMide
Benzamide, N-(1-acetyl-4-piperidinyl)-4-fluoro- | [Molecular Formula]
C14H17FN2O2 | [MOL File]
283167-06-6.mol | [Molecular Weight]
264.3 |
| Hazard Information | Back Directory | [Uses]
FK962 is an enhancer of somatostatin release, exerts cognitive-enhancing actions. Anti-dementia properties[1]. | [in vivo]
FK962 (0.1, 0.3 or 1.0 mg/kg; i.p.) and Donepezil (a single dose of 1 mg/kg) act synergistically to improve cognition in rats: as an add-on therapy for Alzheimer's disease[2]. | Animal Model: | Male Lister Hooded rats, weighing approximately 270-300[2] | | Dosage: | 0.1, 0.3 or 1.0 mg/kg; Donepezil was given as a single dose of 1 mg/kg | | Administration: | Administered i.p. | | Result: | Resulted in minimal cognition enhancement when given separately. Combination showed a significantly greater effect on cognition. |
| [References]
[1] Tokita K, et al. FK962, a novel enhancer of somatostatin release, exerts cognitive-enhancing actions in rats. Eur J Pharmacol. 2005 Dec 19;527(1-3):111-20. DOI:10.1016/j.ejphar.2005.10.022
[2] McCarthy AD, et al. FK962 and donepezil act synergistically to improve cognition in rats: potential as an add-on therapy for Alzheimer's disease. Pharmacol Biochem Behav. 2011 Mar;98(1):76-80. DOI:10.1016/j.pbb.2010.11.019 |
|
|